Enhanced community health worker program for cardiovascular disease management

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates an enhanced community health worker (CHW) program aimed at improving cardiovascular disease (CVD) self-management skills among underserved populations in Philadelphia. Participants aged 35-75 with CVD risk factors and unmet social needs will receive the DECIDE+ intervention, which includes bi-weekly group sessions and CHW consultations, or continue with standard CHW services. The study employs a Type 1 Hybrid Effectiveness-Implementation Design and aims to recruit 500 residents to assess improvements in health behaviors and resolution of social needs. The primary outcome will be measured using the Self-care of Chronic Illness Inventory Maintenance scale.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Reside in Philadelphia
* Be between 35 and 75 years of age (inclusive)
* Self-report having been told by a healthcare provider that they have one or more of the following CVD-related chronic conditions:

  1. Pre-diabetes
  2. Diabetes
  3. Hypertension
  4. Hyperlipidemia/ high cholesterol)
  5. BMI \>=30.
* Have completed an initial visit with a CEO CHW
* Have one or more unmet social needs identified in the CEO Intake Form in the following areas:

  1. Housing Stability,
  2. Food security,
  3. Transportation to medical appointments and/or work,
  4. Employment,
  5. Household utilities,
  6. Healthcare access,
  7. Health literacy, and
  8. Social support.
* Willing to consent to participate in the CEAL study regular access to a mobile device to qualify for enrollment.

Exclusion Criteria:

* Does not reside in Philadelphia
* Not between 35 and 75 years of age (inclusive)
* Does not self-report having been told by a healthcare provider that they have one or more of the following CVD-related chronic conditions:

  1. Pre-diabetes
  2. Diabetes
  3. Hypertension
  4. Hyperlipidemia/ high cholesterol)
  5. BMI \>=30.
* Has not completed an initial visit with a CEO CHW
* Does not have one or more unmet social needs identified in the CEO Intake Form in the following areas:

  1. Housing Stability,
  2. Food security,
  3. Transportation to medical appointments and/or work, employment,
  4. Household utilities,
  5. Healthcare access,
  6. Health literacy, and
  7. Social support.
* Unwilling to consent to participate in the CEAL study regular access to a mobile device to qualify for enrollment.

Where it's running

• University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Jose Bauermeister, MPH, PhD — University of Pennsylvania
• Study coordinator: Jose Bauermeister, MPH, PhD
• Email: phillyceal@nursing.upenn.edu
• Phone: 215-898-9993

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Linking social care with healthcare to help manage chronic diseases

  This trial tests whether pairing patients with trained community health workers can help them get transportation, healthy food, information, and better access to care to improve health in conditions like hypertension, diabetes, and high cholesterol.

  Recruiting at 2 sites University of Arizona · Tucson, Arizona and 1 other locations · NCT07799961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.